In Section A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental individuals might be enrolled in the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. In Section https://clinicaleffectivenessofab79023.liberty-blog.com/32180344/a-simple-key-for-abbv-744-for-targeted-cancer-therapy-treatment-unveiled